Amitriptyline down-regulates coenzyme Q10 biosynthesis in lung cancer cells

Eur J Pharmacol. 2017 Feb 15:797:75-82. doi: 10.1016/j.ejphar.2017.01.017. Epub 2017 Jan 15.

Abstract

Amitriptyline, a tricyclic antidepressant, has been proposed as an antitumoral drug in oxidative therapy. Its pro-apoptotic effects, mediated by high reactive oxygen species generation, have been already described. In this study we analysed the effect of amitriptyline on the biosynthesis of coenzyme Q10 (CoQ), an essential component for electron transport and a potent membrane antioxidant involved in redox signaling. We treated H460 cells, a non-small-cell lung cancer cell line, with amitriptyline and we analysed CoQ levels by HPLC and CoQ biosynthesis rate, as well as the enzymes involved in CoQ biosynthesis by real-time PCR and Western blot. Amitriptyline treatment induced a dose-dependent decrease in CoQ levels in tumor cells. CoQ decreased levels were associated with down-regulation of the expression of COQ4 gene, as well as decreased Coq4 and Coq6 protein levels. Our findings suggest that the effect of amitriptyline on CoQ biosynthesis highlights the potential of this drug for antitumoral oxidative therapy.

Keywords: Amitriptyline; Antioxidants; Coenzyme Q(10); Oxidative stress; Oxidative therapy.

MeSH terms

  • Amitriptyline / pharmacology*
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Humans
  • Kinetics
  • Lung Neoplasms / pathology*
  • Reactive Oxygen Species / metabolism
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / biosynthesis
  • Ubiquinone / metabolism

Substances

  • Reactive Oxygen Species
  • Ubiquinone
  • Amitriptyline
  • coenzyme Q10